Comment is a neurosurgical emergency? All, none or some? Outcome is largely determined by age and grade of presentation. Although the elderly generally fair less well, age is no longer a contraindication for definitive treatment. The incidence of rebleeding after initial SAH is between 9-17% of patients, with most cases occurring within six hours of the initial bleed. 3 Mortality in patients who rebleed is up to 80%. Rebleeding is more common in patients in poor clinical condition, with large aneurysms, those with loss of consciousness or sentinel headache. Repair of a ruptured aneurysm by either coil embolisation or microsurgical clipping will significantly reduce the risk of rebleeding. 4 That argues for immediate transfer of all SAH patients for consideration of early angiography and securing of the aneurysm if identified. The resource implications are significant, not just at the neurosurgical centre but also at the DGH who would need to transfer the patient.
Should we transfer all patients or just those with good clinical grades? Some patients with initially poor clinical condition may benefit from emergency neurosurgery; 5 intracerebral extension of a SAH occurs in around 1/3 of cases; patients with large haematomas may require surgical evacuation preferably preceded by occlusion of the aneurysm, or hemicraniectomy to allow expansion of swollen brain tissue. Subdural haematomas occur in 2% of SAH and may require removal if causing mass effect.
Management of patients who arrive in a poor condition with enlargement of the ventricular system on initial CT is controversial. Does neurological impairment result from the initial haemorrhage or the hydrocephalus? Some neurosurgical centres will suggest the patient is observed for 24 hours locally. A proportion of patients will improve spontaneously with the initial episode of unconsciousness ascribed to the ictus. These patients should then be transferred for aneurysm management. Other units advocate early transfer and placement of an external ventricular drain with subsequent observation on the neurointensive care unit for signs of improvement.
NICE head injury guidance and recommendations from the NHS Clinical Advisory Group on regional networks for major trauma are clear that all severe head injuries should be managed in their regional neurosciences centre. The development of hyperacute stroke centres may result in similar recommendations for patients with SAH. In the meantime we are likely to continue with regional and individual variations in care. Neurosurgical centres must be clear about their indications for admission and reasons for refusal. Lack of capacity is no longer acceptable as a reason to delay admission and centres must continue to own patients who are initially admitted into DGHs, without suggesting transfer to other units. Critical care networks should compile records of delayed or refused admissions to regional units. The RAIN study will report in March 2012 on the outcomes and cost-effectiveness of care for traumatic brain injury in neurosciences centres versus DGHs. 6 Perhaps the next study should do the same for SAH? 
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Competence of trainee doctors responsible for high dependency patients
W e report the results of an audit carried out in the NorthWest region of England concerning the management of high dependency patients. According to the Department of Health, in January 2011 there were 1,672 level 2 beds available in England. Of these, 501 were in combined general intensive care/high dependency units and 521 were in separate nonspecialist high dependency units. The others were mainly in specialist units such as cardiothoracic and liver units.
The experience of the authors is that in the North-Western Deanery region, general high dependency patients in separate units are either managed by the parent team with little critical care team input, or vice versa. We have been involved in several incidents where trainees from parent teams have sought help from the critical care team for management of high dependency patients, as the trainees felt they were required to act outside their competence. Therefore, we undertook a survey to assess the competence of non-critical care trainees managing high dependency patients.
The first part of the survey was telephone-based, involving all 20 high dependency units in the region. We found that in 45% (9/20) of high dependency units, patients were managed by the critical care team, who were actively involved in stabilising patients. In the remaining 11 units, parent teams managed patients. For those 11 units we asked to speak to a doctor responsible for looking after patients on the unit. We found that nine (82%) of those doctors did not feel competent to insert arterial lines, seven (64%) did not feel competent to insert central lines and four (36%) did not feel competent to manage vasoactive infusions of drugs.
The preliminary survey was followed with an internet-based 
Is ventilator-associated pneumonia (VAP) an appropriate quality indicator? 'Quality means doing it right when no one else is looking' Henry Ford.
I t has been estimated that up to 10% of hospital patients are affected by healthcare-associated infections (HAI), and as many as a third of cases are preventable. Ventilator-associated pneumonia (VAP) is the most common HAI in intensive care units (ICUs) with a reported incidence between 9 and 28%. 1, 2 Studies have demonstrated that VAP increases morbidity, number of ventilator days and length of both ICU and hospital stay. 3 Moreover, it constitutes a significant economic burden for every patient. Each VAP infection is estimated to increase patient care cost by £6,000-£22,000. 4 Considering the significant clinical and financial implications, it is unsurprising that NHS targets have increasingly focused on outcome measures related to hospitalacquired infection. Failure of NHS organisations to effectively audit policies and to implement procedures to prevent infection can now result in penalties, suspension and even closure. 5 In the United States, insurance companies regard this apparent failing in patient care as a breach of contract. On this basis, the Centers for Medicare and Medicaid Services have stopped reimbursing hospitals when patients suffer nosocomial infections such as vascular catheter-related bloodstream infections and catheter-associated urinary tract infections. The proposal that VAP is to become the next 'preventable complication' has been raised but so far has been met with disapproval by clinicians. 6 Whether this objection will be sustained is not yet clear. If VAP does ultimately become a marker of failing standards or poor performance, we will no doubt see these same arguments transferred to the UK.
Until an acceptable 'gold standard' is agreed for diagnosing VAP, comparison between units to determine quality and tariff on the basis of VAP incidence cannot be justified. Diagnosing VAP correctly and reliably is challenging, as current definitions lack the necessary diagnostic discrimination. NICE guidance of 2008 refers to VAP as a pneumonia in a 'mechanically ventilated patient that develops 48 hours or more after intubation with an endotracheal or tracheostomy tube that was not present before intubation.' 7 However, many conditions common in ICU patients, such as ARDS, sepsis, cardiac failure and lung atelectasis have similar clinical signs. As a consequence, more than 50% of patients diagnosed with VAP do not have the disease, whereas up to one third of patients with VAP are not actually diagnosed. 8, 9 Scoring systems provide a method of pooling data to determine the likelihood of a positive or negative diagnosis. The Clinical Pulmonary Infection Score (CPIS), 10 Centre for Diseases Control and Prevention National Healthcare Safety Network (CDC-NHSN) Definition 11 and the Hospitals in Europe Link for Infection Control through Surveillance (HELICS) criteria 12 are recognised systems. The CPIS, which incorporates only qualitative microbiological analysis, is the most commonly used scoring system in the UK (Wong A, Mathieu S, Williams M; unpublished data). HELICS is widely used in Europe and relies on a combination of clinical, radiological and microbiological criteria. Unfortunately, these scoring systems and definitions lack the necessary sensitivity and specificity required of a 'gold-standard' diagnostic tool. In addition, the subjectivity of individual domains (clinical signs, radiology, microbiology sampling) has meant a considerable variation in interpretation by clinicians and therefore similar discrepancy in the reported incidence rates of VAP.
Even given a reliable, robust and accurate system for recognising VAP, at what point in the continuum between lower respiratory tract colonisation and infection with pathogenic microorganisms does VAP become a distinct entity? Is it truly preventable with current measures? Do the surrogate
